Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2008;336:107-108 (19 January), doi:10.1136/bmj.39421.440799.BE
Should be evidence based, flexible, and tailored to patients lifelong needs
| The first 150 words of the full text of this article appear below. |
More than 1.2 million women and men worldwide are diagnosed with breast cancer each year. In 2007, the 20 year survival rate for breast cancer will be greater than the five year survival rate 30 years ago.1 Breast cancer is now recognised as a chronic disease that can recur even after 20-30 years. Follow-up protocols vary widely—both within and between countries—and are not always evidence based. The challenge is to develop follow-up programmes that reflect current knowledge and meet the ongoing needs of this growing number of people.
Guidelines from the National Institute for Health and Clinical Excellence (NICE) in England and Wales state that the aims of breast cancer follow-up are to detect and treat local recurrence, to deal with adverse effects of treatment, and to provide psychological support.2 Routine surveillance for metastatic disease is not recommended because data from randomised studies have shown no improvement in outcomes for
J M Dixon, consultant surgeon and senior lecturer in surgery; clinical director, Edinburgh breakthrough research unit1, David Montgomery, clinical research fellow2
1 Edinburgh Breast Unit, Western General Hospital, Edinburgh EH4 2XU, 2 Department of Surgery, Glasgow Royal Infirmary, Glasgow G4 0SF
jmd@ed.ac.uk
Read all Rapid Responses
Israeli students are refusing to perform intimate examinations on anaesthetised women without their informed consent.